PL3046934T3 - Białko fuzyjne - Google Patents

Białko fuzyjne

Info

Publication number
PL3046934T3
PL3046934T3 PL14772194T PL14772194T PL3046934T3 PL 3046934 T3 PL3046934 T3 PL 3046934T3 PL 14772194 T PL14772194 T PL 14772194T PL 14772194 T PL14772194 T PL 14772194T PL 3046934 T3 PL3046934 T3 PL 3046934T3
Authority
PL
Poland
Prior art keywords
fusion protein
fusion
protein
Prior art date
Application number
PL14772194T
Other languages
English (en)
Inventor
Simon Westbrook
Original Assignee
Levicept Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Levicept Ltd filed Critical Levicept Ltd
Publication of PL3046934T3 publication Critical patent/PL3046934T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2807Headache; Migraine
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2842Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL14772194T 2013-09-18 2014-09-18 Białko fuzyjne PL3046934T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1316592.3A GB201316592D0 (en) 2013-09-18 2013-09-18 Fusion protein
EP14772194.8A EP3046934B1 (en) 2013-09-18 2014-09-18 Fusion protein
PCT/GB2014/052833 WO2015040398A1 (en) 2013-09-18 2014-09-18 Fusion protein

Publications (1)

Publication Number Publication Date
PL3046934T3 true PL3046934T3 (pl) 2019-05-31

Family

ID=49552839

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14772194T PL3046934T3 (pl) 2013-09-18 2014-09-18 Białko fuzyjne

Country Status (25)

Country Link
US (3) US9873728B2 (pl)
EP (1) EP3046934B1 (pl)
JP (3) JP6681834B2 (pl)
KR (1) KR102205633B1 (pl)
CN (1) CN105873943B (pl)
AU (1) AU2014322842B2 (pl)
CA (1) CA2924410C (pl)
CY (1) CY1121347T1 (pl)
DK (1) DK3046934T3 (pl)
EA (1) EA037416B1 (pl)
ES (1) ES2714694T3 (pl)
GB (1) GB201316592D0 (pl)
HR (1) HRP20190434T1 (pl)
HU (1) HUE043273T2 (pl)
IL (1) IL244588B (pl)
LT (1) LT3046934T (pl)
MX (1) MX2016003530A (pl)
NZ (1) NZ718044A (pl)
PL (1) PL3046934T3 (pl)
PT (1) PT3046934T (pl)
RS (1) RS58463B1 (pl)
SG (1) SG11201602068QA (pl)
SI (1) SI3046934T1 (pl)
TR (1) TR201903490T4 (pl)
WO (1) WO2015040398A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350312B (es) 2012-03-14 2017-09-01 Levicept Ltd Uso terapeutico de la proteina de union a neurotrofina del receptor neutrofico p75.
GB201316592D0 (en) 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) * 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
GB201504691D0 (en) * 2015-03-19 2015-05-06 Levicept Ltd Fusion protein
EP3711772A1 (en) 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
CN113456799A (zh) * 2020-12-25 2021-10-01 苏州澳宗生物科技有限公司 一种p75ECD在制备用于调节疼痛的药物中的应用
CN112851794B (zh) * 2021-02-04 2023-05-23 苏州铂维生物科技有限公司 一种基于cd271的抗原表位及其应用
AU2022369106A1 (en) * 2021-10-21 2024-04-11 Petmedix Ltd Proteins comprising the extracellular domain of p75ntr
US11608371B1 (en) * 2021-10-21 2023-03-21 Petmedix Ltd Therapeutic molecules

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
WO2006079176A1 (en) * 2005-01-28 2006-08-03 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
WO2007026567A1 (ja) 2005-08-30 2007-03-08 National University Corporation Chiba University p75NTR阻害剤を有効成分として含有する鎮痛剤
EP1978997A1 (en) * 2005-12-22 2008-10-15 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
GB0717985D0 (en) * 2007-07-20 2007-10-24 Asterion Ltd Growth hormone fusion proteins
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
US20100061981A1 (en) 2008-08-15 2010-03-11 The Salk Institute For Biological Studies p75NTR MEDIATES EPHRIN-A REVERSE SIGNALING
WO2010117786A1 (en) * 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
JP6016636B2 (ja) * 2009-10-15 2016-10-26 ジェネンテック, インコーポレイテッド 改変したレセプター特異性を持つキメラ線維芽細胞増殖因子
WO2011068993A1 (en) * 2009-12-02 2011-06-09 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life of fc fusion proteins.
CN102233128B (zh) 2010-11-26 2013-04-17 王延江 一种p75NTR-ECD在防治阿尔茨海默病药物中应用
ITRM20110024A1 (it) 2011-01-24 2012-07-25 Consiglio Nazionale Ricerche Uso di antagonisti del recettore p75ntr e/o di agonisti del recettore trka per il trattamento delle malattie infiammatorie croniche.
US20130078250A1 (en) * 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
TWI476001B (zh) * 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Fc融合蛋白及其用途
CN102586313A (zh) 2012-03-05 2012-07-18 中国人民解放军第三军医大学野战外科研究所 p75NTR-ED-Fc融合蛋白的制备方法及其在损伤中枢神经再生与功能恢复中的应用
MX350312B (es) 2012-03-14 2017-09-01 Levicept Ltd Uso terapeutico de la proteina de union a neurotrofina del receptor neutrofico p75.
EP2674439B1 (en) * 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
GB201316592D0 (en) 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
GB201504691D0 (en) 2015-03-19 2015-05-06 Levicept Ltd Fusion protein

Also Published As

Publication number Publication date
GB201316592D0 (en) 2013-10-30
IL244588B (en) 2019-12-31
SG11201602068QA (en) 2016-04-28
BR112016006113A2 (pt) 2017-09-26
KR20160058872A (ko) 2016-05-25
WO2015040398A1 (en) 2015-03-26
EP3046934B1 (en) 2018-12-12
JP2020062011A (ja) 2020-04-23
HRP20190434T1 (hr) 2019-04-19
CA2924410A1 (en) 2015-03-26
CY1121347T1 (el) 2020-05-29
TR201903490T4 (tr) 2019-03-21
MX2016003530A (es) 2016-10-13
CA2924410C (en) 2023-01-24
KR102205633B1 (ko) 2021-01-20
RS58463B1 (sr) 2019-04-30
ES2714694T3 (es) 2019-05-29
AU2014322842B2 (en) 2018-08-16
LT3046934T (lt) 2019-03-25
JP2016531590A (ja) 2016-10-13
IL244588A0 (en) 2016-04-21
NZ718044A (en) 2020-07-31
US20210238256A1 (en) 2021-08-05
DK3046934T3 (en) 2019-04-08
JP7357088B2 (ja) 2023-10-05
US20180273603A1 (en) 2018-09-27
US10988526B2 (en) 2021-04-27
EA037416B1 (ru) 2021-03-25
AU2014322842A1 (en) 2016-04-07
CN105873943B (zh) 2023-04-07
US20160222082A1 (en) 2016-08-04
CN105873943A (zh) 2016-08-17
JP2022068253A (ja) 2022-05-09
EP3046934A1 (en) 2016-07-27
JP6681834B2 (ja) 2020-04-15
HUE043273T2 (hu) 2019-08-28
EA201690469A1 (ru) 2016-12-30
PT3046934T (pt) 2019-03-25
SI3046934T1 (sl) 2019-04-30
US9873728B2 (en) 2018-01-23

Similar Documents

Publication Publication Date Title
IL284301A (en) Heterodimeric proteins
IL281703A (en) New heterodimeric proteins
EP2895819A4 (en) SENSOR FUSION
EP2943512A4 (en) FUSION BOVINE ANTIBODIES
EP2968551A4 (en) FUSION PROTEINS AND METHOD THEREFOR
HRP20190434T1 (hr) Fuzijski protein
HK1216159A1 (zh) 治療性融合蛋白
EP2992992A4 (en) CONNECTION OF DIFFERENT MATERIALS
HK1220903A1 (zh) 軟骨結合型融合蛋白
HK1231494A1 (zh) 殺蟲融合蛋白改進
EP2969009A4 (en) MODIFIED FC FUSION PROTEINS
GB201308057D0 (en) Protein
GB201401955D0 (en) Protein
GB201304973D0 (en) Recombinant protein
GB201314945D0 (en) Protein crystals
GB201304115D0 (en) Fusion ploypeptide
GB201302031D0 (en) Protein
GB201302030D0 (en) Protein
GB201309812D0 (en) MK-V fusion system
GB201300381D0 (en) Peptides